Ebola virus (EBOV) in humans causes a severe illness with high mortality rates. Several strategies have been developed in the past to treat EBOV infection, including the antibody cocktail ZMapp, which has been shown to be effective in nonhuman primate models of infection 1 and has been used under compassionate-treatment protocols in humans 2 . ZMapp is a mixture of three chimerized murine monoclonal antibodies (mAbs) 3-6 that target EBOV-specific epitopes on the surface glycoprotein 7,8 . However, ZMapp mAbs do not neutralize other species from the genus Ebolavirus, such as Bundibugyo virus (BDBV), Reston virus (RESTV) or Sudan virus (SUDV). Here, we describe three naturally occurring human cross-neutralizing mAbs, from BDBV survivors, that target an antigenic site in the canonical heptad repeat 2 (HR2) region near the membrane-proximal external region (MPER) of the glycoprotein. The identification of a conserved neutralizing antigenic site in the glycoprotein suggests that these mAbs could be used to design universal antibody therapeutics against diverse ebolavirus species. Furthermore, we found that immunization with a peptide comprising the HR2-MPER antigenic site elicits neutralizing antibodies in rabbits. Structural features determined by conserved residues in the antigenic site described here could inform an epitope-based vaccine design against infection caused by diverse ebolavirus species.
Ebola virus (EBOV) in humans causes a severe illness with high mortality rates. Several strategies have been developed in the past to treat EBOV infection, including the antibody cocktail ZMapp, which has been shown to be effective in nonhuman primate models of infection 1 and has been used under compassionate-treatment protocols in humans 2 . ZMapp is a mixture of three chimerized murine monoclonal antibodies (mAbs) [3] [4] [5] [6] that target EBOV-specific epitopes on the surface glycoprotein 7, 8 . However, ZMapp mAbs do not neutralize other species from the genus Ebolavirus, such as Bundibugyo virus (BDBV), Reston virus (RESTV) or Sudan virus (SUDV). Here, we describe three naturally occurring human cross-neutralizing mAbs, from BDBV survivors, that target an antigenic site in the canonical heptad repeat 2 (HR2) region near the membrane-proximal external region (MPER) of the glycoprotein. The identification of a conserved neutralizing antigenic site in the glycoprotein suggests that these mAbs could be used to design universal antibody therapeutics against diverse ebolavirus species. Furthermore, we found that immunization with a peptide comprising the HR2-MPER antigenic site elicits neutralizing antibodies in rabbits. Structural features determined by conserved residues in the antigenic site described here could inform an epitope-based vaccine design against infection caused by diverse ebolavirus species.
In previous work, we described a large panel of neutralizing monoclonal antibodies (mAbs) using peripheral blood B cells from survivors of the 2007 BDBV outbreak in Uganda 9 . Three non-clonally related cross-reactive mAbs designated BDBV223, BDBV317 and BDBV340 were isolated from two donors who survived BDBV infection. These three mAbs competed for binding with BDBVspecific neutralizing mAbs that bound to an epitope extending down below the base of the glycoprotein (GP), a domain that is poorly characterized as an antigen in filovirus GPs 9 .
To delineate the binding sites of these cross-reactive mAbs on GPs, we performed quantitative competition-binding assays with BDBV223, BDBV317 and BDBV340 as well as with previously described ebolavirus-specific mAbs targeting the glycan cap or the GP base (Fig. 1a) . As expected, BDBV223, BDBV317 and BDBV340 did not compete with either the glycan cap-specific mAb c13C6 or the base region-binding mAb c4G7 (Fig. 1a) . To determine the location of the cross-reactive antigenic site on the GP stem region targeted by these human mAbs, we performed negative-stain singleparticle electron microscopy studies. The electron microscopy class averages confirmed that BDBV223, BDBV317 and BDBV340 each bind to the bottom of the GP, in the canonical HR2 domain near the MPER (Fig. 1b,c) . To confirm their location on the GP, we overlaid a class average of BDBV223 Fab bound to BDBV GP with a class average of c13C6 Fab:c4G7 Fab bound to EBOV GP. This showed that BDBV223, BDBV317 and BDBV340 bound to a region on the GP closer to the viral membrane, well below the epitope of the mAb c4G7 site of vulnerability at the GP1-GP2 interface 7 ( Fig. 1d) . Measurements of the distance from the bottom of the GP globular head to the mid-point of the Fab in the class averages showed a distance of ~60 Å, which indicates that Fabs bind to the HR2 region (Protein Data Bank identifier (PDB ID): 5JQ3) , they failed to neutralize SUDV (Fig. 2a) . Previously, we identified species-specific neutralizing human mAbs that bound the BDBV GP near to the MPER region and competed for binding with the cross-reactive mAbs BDBV223, BDBV317 and BDBV340, although their epitopes were not determined 9 . Recently, another group isolated several EBOV neutralizing mAbs that recognize the GP stalk region 12 . One HR2-MPER-specific mAb (ADI-16061) from that antibody panel was reported to neutralize vesicular stomatitis viruses bearing EBOV, BDBV and Taï Forest virus GPs 13 . In addition, a previous study described the generation of a rabbit crossreactive non-neutralizing mAb, 15H10, that bound to peptides corresponding to the HR2-MPER region 14 . Thus, the HR2-MPER region is a complex antigenic site on GPs that could be targeted by species-specific or cross-reactive as well as neutralizing or nonneutralizing antibodies.
To determine the protective capacity of HR2-MPER-specific mAbs, we tested cross-reactive antibodies in mice against a heterologous mouse-adapted EBOV, strain Mayinga. Two mAbs (BDBV223 and BDBV317) provided complete protection from death when delivered 1 day after challenge with heterologous EBOV (Fig. 2b and Supplementary Fig. 2 ). BDBV223 and BDBV317 also conferred partial protection against heterologous EBOV in guinea pigs when delivered 24 hours after the virus challenge ( Fig. 2c and Supplementary Fig. 2 ). Finally, we tested BDBV223 in a ferret model of BDBV infection, which is one of only two models described for BDBV challenge (the other is nonhuman primates) 15, 16 . Animals were treated at day 3 and day 6. All animals treated with the control mAb (2D22; a Dengue virus-specific mAb) succumbed to death at day 7 following challenge. By contrast, two out of four animals treated with the mAb BDBV223 survived the infection (Fig. 2d) .
To map the epitope of cross-reactive human mAbs, we used a comprehensive alanine scanning approach and tested the binding of BDBV223, BDBV317 and BDBV340 to individual members of a shotgun mutagenesis alanine scan library of the EBOV GP. Consistent with the electron microscopy data, we identified critical contact residues in GP2 for BDBV223, BDBV317 and BDBV340 that spanned the carboxy-terminal part of the HR2 region and the amino-terminal part of the MPER region (Fig. 3a) . Single critical residues in the HR2 region were identified for BDBV317 (K633) and BDBV340 (D624). Two critical residues (D624 and D632) were identified for BDBV223 ( Fig. 3a and Supplementary Table 1 ). For comparison, we also indicate the location of several critical residues identified previously for c4G7, including D552 in the internal fusion loop and C556, which is part of the HR1 region (ref. 8 ).
We passaged the chimeric filovirus with the BDBV GP 17 in the presence of HR2-MPER-specific mAbs and generated antibody escape mutant viruses for the mAbs BDBV223 (an isolate with a P634H mutation), BDBV317 (an isolate with the K633R mutation) and BDBV340 (an isolate with the D522E mutation). We found that the BDBV223 P634H escape mutant resisted neutralization by all three HR2-MPER mAbs. BDBV223 and BDBV340 neutralized the BDBV317 escape mutant virus with ~100-fold lower potency than the wild-type virus (Fig. 3b) . The BDBV340 escape mutant virus (D522E) was completely resistant to neutralization by BDBV340 and BDBV317 and only weakly neutralized by BDBV223. Interestingly, the D522E mutation is located in the internal fusion loop region outside of the expected epitope for these mAbs and probably causes conformational changes that affect the binding of HR2-MPERspecific mAbs.
According to several crystallographic studies, the HR2 α -helix ends around residue D632 (refs 10, 11, 18 ), indicating that HR2-MPER peptides might adopt an α -helical conformation that is recognized 
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by the ebolavirus cross-reactive mAbs. To determine whether BDBV223, BDBV317 or BDBV340 can recognize a linear conserved epitope in the HR2-MPER region, we synthesized peptides spanning the GP amino acids 620-635 in the HR2-MPER region of three virus species (designated peptides BDBV2, EBOV2 and SUDV2) as well as a control peptide from the N terminus of the HR2 region (amino acids 599-613), designated the BDBV1 peptide. The mAbs BDBV223, BDBV317 and BDBV340 recognized the BDBV2 peptide containing the critical residues that were determined by alanine scanning mutagenesis, but not the negative control BDBV1 peptide from the HR2 region, as expected (Fig. 3c) . Although BDBV223 bound to the BDBV2, EBOV2 and SUDV2 peptides, BDBV317 and BDBV340 recognized only the BDBV2 and EBOV2 peptides (Fig. 3c,d ). The binding capacities of the three mAbs to the HR2-MPER peptides (Fig. 3c,d ) were consistent with their neutralization potencies in vitro (Fig. 2a) . Thus, BDBV317 bound equally well to the BDBV2 and EBOV2 peptides and neutralized BDBV and EBOV with the same potency. BDBV223 and BDBV340 bound better to the BDBV2 peptide, and the same antibodies neutralized BDBV with higher potency than EBOV. These results suggest that the mAbs recognize a relatively linear peptide epitope in the HR2-MPER region. In a recent study, the HR2 and the N-terminal part of the MPER were reported to be proximal to the lipid bilayer 19 , which would make the HR2-MPER epitope accessible for antibody binding on the viral surface.
To determine the basis of mAb cross-reactivity to multiple ebolavirus species, we synthesized a panel of chimeric BDBV peptides containing polymorphic residues from EBOV or SUDV. There are two amino acid differences between the BDBV2 and EBOV2 peptides (at residues 631 and 634), located in the C terminus of the peptide (Fig. 3a,d ). To determine which substitutions were responsible for the better binding of BDBV223 to the BDBV2 peptide, we synthesized two chimeric BDBV peptides with single EBOV substitutions at residues 631 or 634 (designated peptides BDBV2A and BDBV2B). BDBV223 bound equally well to the BDBV2 and BDBV2A peptides, whereas it bound relatively weakly to the BDBV2B peptide, suggesting that the P634T substitution in the BDBV2B peptide is responsible for the reduced binding of BDBV223 to the EBOV2 peptide (Fig. 3c,d ). We also synthesized chimeric BDBV2C and BDBV2D peptides to introduce two SUDV substitutions at residues 624 and 633. Although both BDBV223 and BDBV317 bound equally well to the BDBV2D and BDBV2 peptides, they failed to recognize the BDBV2C peptide, suggesting that the N624 residue is critical for the binding of SUDV by HR2-MPER-specific mAbs (Fig. 3d) . To investigate the role of residue D624 in the context of live virus neutralization, we constructed a recombinant BDBV bearing the D624N mutation, which completely resisted neutralization with BDBV223 and BDBV340 but was sensitive to BDBV317 ( Supplementary Fig. 3 ).
To determine the immunogenicity of HR2-MPER peptides, we set up immunization experiments with the BDBV2 (Fig. 4 , animals 1 and 2) and SUDV2 ( c, Post-exposure protection of EBOV-inoculated guinea pigs treated with BDBV223, BDBV317 or a control mAb (2D22) 1 day after EBOV challenge (n = 5 animals per group). Kaplan-Meier survival curves are shown. d, Post-exposure protection of BDBV-inoculated ferrets treated with BDBV223 or a control mAb (2D22) at day 3 and day 6 after BDBV challenge (n = 4 animals per group). Kaplan-Meier survival curves are shown. Separate two-sided log-rank (Mantel-Cox) tests were used for pairwise comparisons of survival curves between each BDBV mAb-treated group and control 2D22-treated mAb group (b-d). P values were not adjusted for multiple comparisons: P ≤ 0.05 was considered significant; NS, not significant.
Letters
NATURE MicROBiOlOgy
peptide-reactive IgG response in serum (Fig. 4a) . We next isolated affinity-purified polyclonal antibodies using a BDBV2p-coupled or SUDV2p-coupled resin for capturing antibodies that bind to HR2-MPER peptides and filovirus GPs. In ELISA, the immunoaffinity-purified polyclonal antibodies displayed broad cross-reactivity, binding to peptides (BDBV2p, EBOV2p and SUDV2p) and 
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GPs (BDBV, EBOV and SUDV) from multiple ebolavirus species (Fig. 4b,c ). Finally, we tested polyclonal antibodies in a neutralization experiment against BDBV, EBOV and SUDV. Immunization with BDBV2p-PEG6-KLH or SUDV2p-PEG6-KLH formulations elicited BDBV-specific or SUDV-specific neutralizing polyclonal antibodies (Fig. 4d) , suggesting the feasibility of an HR2-MPER peptide-based vaccine approach to elicit ebolavirus-specific neutralizing antibodies. We also detected weak neutralization against heterologous ebolavirus species at the highest antibody concentrations tested in animals 1, 2 and 4. Animal 3, immunized with the SUDV2p-PEG6-KLH formulation, developed cross-neutralizing response to three ebolavirus species: BDBV, EBOV and SUDV. Future studies are needed to determine the optimal conformation of the HR2-MPER peptide and the formulation of peptide immunogen to elicit potent ebolavirus cross-neutralizing antibody response. Here, we describe human cross-reactive, neutralizing and protective mAbs that target an antigenic region near the MPER region of the EBOV GP. These antibodies recognize a distinct antigenic site and, therefore, do not compete for binding with therapeutic antibodies used in the past to treat EBOV infection. This finding suggests that MPER-specific mAbs could be used to design a new antibody therapeutic cocktail with broader potency against multiple ebolaviruses. Increased breadth and potency can be achieved by combining HR2-MPER-specific mAbs with previously described potent cross-reactive mAbs that target other conserved epitopes in the glycan cap 9, 12, 13 , the GP base 12, 13 and the internal fusion loop 20 . Alternatively, the mAbs described here might be beneficial to include in existing experimental therapeutic antibody cocktails to increase the breadth of those cocktails.
The MPER region in the GP of enveloped viruses is increasingly recognized as an important region for recognition by broad and potent human mAbs. Several mAbs that neutralize a broad range of human immunodeficiency virus (HIV) 21, 22 isolates are known to bind to conserved epitopes in the HIV gp41 MPER region. The identification of potent HIV MPER-specific mAbs has spurred important progress in the effort to design HIV vaccines rationally using antigens that are designed to induce such mAbs 23 . Neutralizing mAbs that recognize the influenza haemagglutinin surface protein stem region [24] [25] [26] have also spurred research into the possibility of a universal influenza vaccine. Here, we report the structural and functional features of conserved epitopes in the MPER region of the EBOV GP that could inform the design of an MPER-based universal vaccine that is effective against multiple filoviruses. ) (InvivoGen) at 27 °C. All cell lines were tested on a monthly basis for mycoplasma and were found to be negative in all cases.
Human mAb and Fab expression and purification. Human hybridoma cell lines were expanded in post-fusion medium, as previously described 27 . HiTrap Protein G or HiTrap MabSelectSure columns (GE Healthcare) were used to purify antibodies from filtered culture supernatants. Fab fragments were generated by papain digestion, as described previously 27 . Expression and purification of filovirus GPs. The EBOV GP ectodomains containing the mucin-like domains and lacking the transmembrane region (EBOV GPΔ TM) (residues 1-636; strain Makona; GenBank: KM233070), BDBV GPΔ TM (residues 1-643; strain 200706291 Uganda; GenBank: NC_014373) and SUDV GPΔ TM (residues 1-637, strain Gulu; GenBank: NC_006432) were expressed transiently in Expi293F cells with a C terminus strep II tag using the pcDNA3 plasmid vector. Secreted proteins were purified using a 5-ml StrepTrap HP column (GE Healthcare) following the manufacturer's protocol, and then purified further and buffer exchanged into PBS using Superdex 200 (GE Healthcare) size exclusion chromatography. The recombinant BDBV GP ectodomain lacking residues 312-463 of the mucin-like domain (GPΔ muc) 28, 29 was produced by transfection of Drosophila S2 cells with modified pMTpuro vectors, followed by stable selection of transfected cells with 6 μ g ml -1 puromycin. Secreted GP ectodomain expression was induced with 0.5 mM CuSO4 for 4 days. Proteins were engineered with a modified double strep tag at the C terminus (the enterokinase cleavage site followed by a strep tag/linker/strep tag) to facilitate purification using Strep-Tactin resin (Qiagen). Proteins were purified further by Superdex 200 size exclusion chromatography in 10 mM Tris and 150 mM NaCl, pH 7.5 (1× TBS).
Antibody neutralization experiments.
All work with filoviruses, including the chimeric filoviruses, was performed in the animal biosafety level 4 (ABSL-4) facility of the Galveston National Laboratory, University of Texas Medical Branch (UTMB). Antibody neutralization assays were performed against the recombinant EBOV strain Mayinga expressing green fluorescent protein from an added gene 30 and its derivatives in which the GP was replaced with its counterpart from BDBV (strain 200706291 Uganda) or SUDV (strain 200011676 Gulu) 17 to which we refer as EBOV, BDBV and SUDV for simplicity. In some antibody neutralization experiments, biological isolates of additional viruses were used: EBOV strain Mayinga (Fig. 2a) , EBOV strain Makona-Gueckedou-C07, accession number KJ660347.2 ( Supplementary Fig. 1 ), RESTV strain 119810 Reston RIID Mky 53 (Fig. 2a) and RESTV strain 200809254 Plum Island (Philippines) ( Supplementary  Fig. 1 ). The assays were performed in a high-throughput format, as previously described 17 , or using a standard plaque reduction assay, as previously described 9 .
Generation of recombinant BDBV with the D624N mutation. To introduce the D624N mutation in the BDBV GP of the chimeric filovirus used in the study 17 , the pEBOwtΔ BamHI-SbfI,AscI-PspOMI subclone of the full-length clone encoding the viral genome 17 was mutagenized using the QuikChange site-directed mutagenesis kit (Stratagene). Then, the ApaI-SacI fragment of the subclone, which includes the mutated GP, was used to replace the corresponding fragment of the chimeric filovirus full-length clone. The mutated chimeric virus was recovered as previously described 31 .
Generation and testing of antibody escape filovirus mutants. To generate escape mutants, 100 plaque-forming unit (p.f.u.) of recombinant chimeric EBOV with GP derived from BDBV were combined with 2-fold dilutions of mAbs starting at 200 µ g ml -1 in U-bottom 96-well plates and incubated for 1 h at 37 °C. Mixtures were placed on Vero E6 cell monolayer cultures in 96-well plates and incubated for 1 h. Supernatants were removed, fresh mAbs were added at the same concentrations in 200 µ l MEM supplemented with 2% FBS and plates were incubated for 7 days at 37 °C. Viruses that replicated in the presence of the highest concentrations of mAbs, as determined by UV microscopy, were collected. Aliquots (20 µ l) were incubated with 2-fold dilutions of mAbs starting at 200 µ g ml -1 , and viruses were propagated in the presence of mAbs as above. The procedure was repeated once more with mAb dilutions starting at 400 µ g ml -1 . Viruses that replicated at the highest mAb concentrations were amplified in Vero E6 cell culture monolayers in 24-well plates in the presence of mAbs at 200 µ g ml -1 for 7 days. Cells were used for isolation of RNA using TRIzol reagent, and GP gene open reading frames were PCR-amplified and sequenced. To determine the susceptibility of the isolated escape mutants to mAbs, 100 p.f.u. of the viruses in MEM supplemented with 2% FBS in triplicate were combined in U-bottom 96-well plates with 8-12 2-fold dilutions of mAbs, starting at 200 μ g ml -1 , in total volumes of 50 µ l, and incubated for 1 h at 37 °C. The virus-antibody mixtures then were placed in triplicate Vero E6 cell culture monolayers in 96-well plates, incubated for 1 h at 37 °C, washed with MEM, overlaid with 200 μ l MEM containing 2% FBS and 0.8% methylcellulose and incubated for 48 h at 37 °C. Plates were fixed with 10% phosphate-buffered formalin (Fisher) and taken out of the ABSL-4 facility according the UTMB ABSL-4 standard operating procedures. Plaques were counted using a fluorescence microscope.
Biolayer interferometry competition-binding assay. Competition-binding studies using biolayer interferometry and biotinylated EBOV GP (EZ-Link Micro NHS-PEG4-Biotinylation Kit; 21955, Thermo Scientific) (5 μ g ml -1 ) were performed on an Octet RED biosensor (ForteBio), as described previously 27 . In brief, the antigen was immobilized onto streptavidin-coated biosensor tips. After a brief washing step, the biosensor tips were first immersed into the wells containing primary antibody at a concentration of 100 μ g ml -1 and then into the wells containing competing mAbs at a concentration of 100 μ g ml -1 . The per cent binding of the competing mAb in the presence of the first mAb was determined by comparing the maximal signal of the competing mAb applied after the first mAb complex to the maximal signal of the competing mAb alone.
Electron microscopy. To determine the epitope of HR2-MPER-directed mAbs, BDBV223, BDBV317 or BDBV340 Fabs were generated as described above and added in 10 M excess to BDBV GPΔ muc and allowed to bind overnight at 4 °C 9 . Complexes were subsequently purified by size exclusion chromatography on a Superdex 200 Increase column (GE Healthcare) and stained as previously described 7 . Particles were visualized using an FEI Tecnai Spirit electron microscope operating at 120 kV, and images were collected on a TVIPS TemCam-F416 (4 k × 4 k) charge-coupled device (CCD) camera using Leginon 32 with the following settings: magnification of × 52,000 that resulted in a pixel size of 2.05 Å at the specimen plane, a constant defocus of -1.00 µ m and an electron dosage of ~30 e -per Å 2 . Images were processed using the Appion platform 33 . Particles were picked using DoG Picker 34 , stacks were created and two-dimensional reference-free class averages were generated using iterative MRA-MSA 35 . For all complexes, there was a strong bias towards side views. Furthermore, the region containing the HR2-MPER epitope in our soluble GP constructs is flexible, as indicated by the various positions that bound Fabs adopted in the class averages. Thus, our data were refractory to a reconstruction, although class averages could be compared to previous class averages of known complexes to determine the spatial location of the epitope on the GP.
Epitope mapping using an EBOV GP alanine scanning mutation library. Epitope mapping was carried out as described previously 8 . Comprehensive highthroughput alanine scanning ('shotgun mutagenesis') was carried out on a fulllength EBOV GP expression construct (based on the Yambuku-Mayinga variant GP sequence), mutagenizing GP residues 33-676 to create a library of clones, each representing an individual point mutant. Residues were changed to alanine (with alanine residues changed to serine). The resulting library, covering 641 out of the 644 (99.5%) target residues, was arrayed into 384-well plates, one mutant per well, then transfected into HEK293T cells and allowed to express for 22 h. Cells, unfixed or fixed in 4% paraformaldehyde, were incubated with primary antibody then with an Alexa Fluor 488-conjugated secondary antibody (Jackson ImmunoResearch Laboratories). After washing, cellular fluorescence was detected using the Intellicyt high-throughput flow cytometer. mAb reactivity against each mutant EBOV GP clone was calculated relative to wild-type EBOV GP reactivity by subtracting the signal from mock-transfected controls and normalizing to the signal from wildtype GP-transfected controls.
Mutated residues within clones were identified as critical to the mAb epitope if they did not support reactivity of the test mAb but did support reactivity of other control EBOV mAbs. This counter-screen strategy facilitated the exclusion of GP mutants that were misfolded locally or that exhibited an expression defect. The detailed algorithms used to interpret shotgun mutagenesis data were described previously 36 .
Peptide synthesis and purification. Peptides were synthesized using standard Fmoc solid-phase methods on a Peptide Machines Discovery-4 synthesizer on rink resin [37] [38] [39] [40] [41] . All coupling reactions were performed with ten-fold excess (versus the load capacity of the resin) of activated amino acid (Aapptec or Advanced Chemtech), using Fmoc amino acids, HBTU, HoBt and DIEA (1:1:1:2.5) in DMF for 60 min. Deprotection of the Fmoc group was accomplished in 20% v/v piperidine diluted in DMF for 30 min. Peptides used for ELISA experiments were acetylated at the N terminus by reaction with 1:1:2 v/v acetic anhydride, DIEA and DMF. The peptides were cleaved by exposure to a 90:5:3:2 v/v mixture of trifluoroacetic acid, thioanisole, ethanedithiol and anisole for 2 h. Peptides were precipitated by the addition of cold diethyl ether, lyophilized and purified by reverse-phase high-performance liquid chromatography (Waters Prep LC 4000) equipped with a Waters 2487 detector and C18 column. Final purified fractions were lyophilized until further use. Isolation of the target peptide was confirmed by matrix-assisted laser desorption/ionization mass spectrometry.
Half-maximum effective concentration ELISA binding analysis. Soluble forms of the full-length extracellular domain of BDBV, EBOV, SUDV or Marburg virus
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. For half-maximum effective concentration (EC 50 ) binding analysis by ELISA, purified antibodies were applied to the plates at 3-fold serial dilutions, starting at 30 μ g ml -1 . The presence of antibodies bound to the GP was determined using a goat anti-human IgG alkaline phosphatase conjugate and p-nitrophenol phosphate substrate tablets, with an optical density read at 405 nm (OD 450 ) after 120 min. A non-linear regression analysis was performed on the resulting curves using Prism version 5 (GraphPad) to calculate EC 50 values.
Testing of mAbs in vivo. The 7-8-week-old BALB/c female mice (Charles River Laboratories) at 5 animals per group were injected with 1,000 p.f.u. of the mouse-adapted EBOV, strain Mayinga, by the intraperitoneal route. Animals were injected with individual mAbs at 100 μ g per animal by the intraperitoneal route 24 h later. Animals treated with 2D22 mAb served as controls. Mice were monitored twice daily from day 0 to day 14 post-challenge, followed by once daily monitoring from day 15 to the end of the study at day 28. The disease was scored using the following parameters: dyspnoea (possible scores: 0-5), recumbency (0-5), unresponsiveness (0-5) and bleeding/haemorrhage (0-5). All mice were euthanized at day 28 post-EBOV challenge. To test the protective efficacy of mAbs in guinea pigs (strain Hartley), 5-6-week-old female guinea pigs at 5 animals per group were injected with 1,000 p.f.u. of guinea pig-adapted EBOV, strain Mayinga, by the intraperitoneal route. Animals were injected with individual mAbs at 5 mg per animal by the intraperitoneal route 24 hours later. Animals were monitored and weighed daily for 28 days. After animals became symptomatic, they were examined no less than two times per day. The disease was scored using the same parameters as used for mice. All guinea pigs were euthanized at day 28 post-EBOV challenge. The animals were randomly assigned for the experimental groups. The UTMB Animal Resource Center veterinary staff was blinded for the administration of antibodies to the experimental groups.
Ferret challenge with BDBV. Groups of 6-month-old male and female animals (Mustela putorius furo, Marshall BioResources) were challenged intramuscularly with 1,000 p.f.u. of BDBV as described previously 16 . Animals were treated with 20 mg of BDBV223 or control 2D22 antibody on day 3, and the same dose of the antibody on day 6 after challenge. The disease scores were assessed as follows: healthy, 1; developing clinical disease, 2; advanced disease, 3; moribund, 4. Ferrets were monitored for 28 days after infection and then euthanized. Five animals per experimental group were used, based on 100% mortality following infection with filoviruses, which allowed statistical assessment at the 95% confidence level (one-tailed Fisher's exact test). The animals were randomly assigned for the experimental groups. The UTMB Animal Resource Center veterinary staff was blinded for the administration of antibodies to the experimental groups.
Analysis of viraemia by plaque assay. Virus titration was performed on serum samples collected from the guinea pigs and ferrets in Vero E6 cells by plaque assay as previously described 17 with some modifications. Briefly, duplicate 10-fold serial dilutions of sera were adsorbed to Vero E6 cell monolayers in 96-well plates for 1 h, covered with 100 µ l 0.9% methylcellulose (SigmaAldrich) overlay and incubated at 37 °C for 6 days. The overlay was removed, cell monolayers were fixed with formalin for 24 h and plates were brought out of ABSL-4 as per UTMB ABSL-4 standard operating procedures. Fixed cell monolayers were washed three times with PBS, blocked for 1 h with 5% skimmed milk in PBS containing 0.1% Tween-20, and plaques were immunostained with rabbit anti-GP primary antibody at 1:5,000 (IBT Bioservices) followed by goat anti-rabbit secondary antibody labelled with horseradish peroxidase at 1:1,000 (Southern Biotech); both antibodies were diluted in 5% skimmed milk in PBS containing 0.1% Tween-20. Virus plaques were visualized by staining with the 4CN 2-Component Peroxidase Substrate System (Seracare).
Polyclonal antibody generation and characterization. New Zealand white rabbits (3-4-months old) were immunized subcutaneously with 0.2 mg HR2-MPER peptide-KLH conjugate consisting of the BDBV2p peptide (TDKIDQIIHDFIDKPL) or the SUDV2 peptide (TDKINQIIHDFIDNPL) conjugated to KLH through the C-terminal cysteine attached to the PEG6 linker (NH-(PEG)6-CH2CH2COOH) in Freund's complete adjuvant (polyclonal antibody service, GenScript). Subsequently, the animals were boosted three times subcutaneously with the same conjugates in Freund's incomplete adjuvant. Filter sterilized pre-immune and test antiserum after the second boost were tested in ELISA for the presence of polyclonal antibodies to BDBV2p or SUDV2p peptides. Polyclonal antibodies were purified using BDBV2p or SUDV2p peptides conjugated to iodoacetyl resin (polyclonal antibody service, GenScript). Purified polyclonal antibodies were tested in ELISA for binding to BDBV2p, EBOV2, SUDV2 or BDBV1 peptides or filovirus GPs. The presence of antibodies bound to the antigen was determined using a mouse anti-rabbit IgG horseradish peroxidase conjugate (A01827-200, GenScript). Polyclonal antibodies were tested in a neutralization assay against the recombinant EBOV expressing green fluorescent protein from an added gene 30 and its derivatives in which the GP was replaced with its counterpart from BDBV or SUDV.
Ethics statement. The animal protocols for testing of mAbs in mice, guinea pigs and ferrets were approved by the Institutional Animal Care and Use Committee of the UTMB in compliance with the Animal Welfare Act and other applicable federal statutes and regulations relating to animals and experiments involving animals. Challenge studies were conducted under maximum containment in an ABSL-4 facility of the Galveston National Laboratory, UTMB. Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
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Experimental design 1. Sample size
Describe how sample size was determined.
The antibodies in this study were previously isolated. The only real sample size calculations pertain to the animal studies. These mouse and guinea pig studies are constrained in that they require BSL-4 challenge facilities, which are a limited resource. We determined the group sizes that would show statistically and biologically meaningful differences based on many years of studies at UTMB on antivirals, antibodies and vaccines for ebolaviruses.
Data exclusions
Describe any data exclusions.
No data were excluded.
Replication
Describe the measures taken to verify the reproducibility of the experimental findings.
Findings presented were based on independent experiments or replicates, as stated in the figure legends. The number of samples was the minimum number required to obtain scientifically valid results. For in vivo experiments, we included justification for group size through a power analysis when possible. All attempts at replication in the stated conditions were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
In Figure 2 , mice and guinea pigs were allocated randomly into each treatment group.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Five animals per experimental group were used, based on 100% mortality following infection with filoviruses, which allowed statistical assessment at the 95% confidence level (1-tailed Fisher exact test). The animals were randomly assigned for the experimental groups. UTMB Animal Resource Center veterinary staff was blinded for the antibodies' administration to experimental groups. Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a third party.
Antibodies described in this paper are available under MTA from Vanderbilt University Medical Center.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
Human antibodies used were generated as part of our study using previously described methods (Flyak AI, Cell 2016; 164: 392-405 . PMC ID 4733404.) The following secondary antibodies were used were validated in the previous study: goat anti-human IgG alkaline phosphatase conjugate (Meridian Life Science #W99008A) and anti-human Alexa Fluor 488-conjugate (Jackson ImmunoResearch Laboratories, Westgrove, PA). c. Report whether the cell lines were tested for mycoplasma contamination.
All cell lines were tested on a monthly basis for Mycoplasma and found to be negative in all cases.
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
No commonly misidentified cell lines were used.
